index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

155

 

 

MOTS CLES

Beta-lactam antibiotics Ustekinumab Alcohol Immune-related adverse events BTK protein Cardio-oncology Pharmacoepidemiology Cardiomyopathy Sipuleucel-T Epidemiology Apre-milast Ethics Biomarkers Ankylosing Burden Adolescent Pregnancy Biosimilar Pharmaceuticals Spondylitis Bacterial Placebo Glucocorticoids Pharmacovigilance Amyloidosis Anxiety Arthritis Albinism Psoriasis Biological therapy Dermatology Biologic therapy Addiction Primary adrenal insufficiency Azathioprine Anxiété ArtThese Auto-Diagnostic Antibiotics Auto-immune hepatitis Vigibase® Anti-TNF Pharmaco-Épidémiologie Anti-HCV Direct Acting Antivirals DAA Alitretinoin Network meta-analysis Cardiotoxicity Drug survival Intensive care Quality of life Apremilast Anticancer drugs Acute Myeloid Leukaemia AML Accelerometer COVID-19 Autoimmune diseases Angiotensin-converting enzyme inhibitors Abus d'antibiotiques Access to care Antimicrobials Infliximab Endocrine toxicity Antimicrobiens Drug reaction Psoriatic arthritis Immunotherapy Etanercept Adverse side effects Biological Therapy Prostate cancer Biologic Cancer Antimicrobial resistance Spondyloarthritis Angiotensin receptor blockers Biologic drug Systematic review Management Axial spondyloarthritis Atrial fibrillation Ankylosing spondylitis Aging Anti-Bacterial Agents Adalimumab Immune checkpoint inhibitors Graft-versus-host disease Arrhythmia Meta-Analysis Sacroiliitis Antimicrobial Stewardship Treatment Stability Bacterial rhinosinusitis Antibiotic misuse ASDAS Biomédicaments Autoimmunity Biologics Méta-Analyse Atopic dermatitis Antibiotic resistance

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS